Pretomanid: From Development to the Implementation of Short-Term Tuberculosis Chemotherapy Regimens: A Literature Review
https://doi.org/10.58838/2075-1230-2026-104-3-88-97
Abstract
The objective: to analyze preclinical and clinical studies on the mechanisms of action, efficacy and safety of the antituberculosis drug pretomanid (PA-824/ F₄₂₀- Pa).
Materials and methods: This review presents the results of 48 publications, including clinical trials evaluating the activity and efficacy of pretomanid (PA-824/ F₄₂₀- Pa) – a member of the nitroimidazopyran class developed for treatment of tuberculosis (TB). This drug is effective against both replicating and persistent Mycobacterium tuberculosis (Mtb), particularly under hypoxic conditions. Preclinical studies demonstrated high activity of Pa against both drug-susceptible and drug-resistant M. tuberculosis. Pa became a key component of the short-term, all-oral regimens, such as BPaL (bedaquiline, pretomanid, and linezolid), for treatment of multidrug-resistant and pre-extensively drug-resistant TB Phase III clinical trials (Nix-TB, ZeNix-TB, and TB-PRACTECAL) confirmed that these regimens achieve cure in just 6 months with a favorable safety profile. Consequently, the duration of effective treatment for drug-resistant TB becomes comparable to that for drug-susceptible TB.
About the Authors
A. I. Gayda
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Anastasiya I. Gayda, Candidate of Medical Sciences Senior Researcher, Department of Differential Diagnosis
and Treatment of Tuberculosis and Concurrent Infections
127473, Moscow, 4 Dostoevsky Street, Building 2;
Tel.: +7 (495) 681-11-66
G. N. Mozhokina
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Galina N. Mozhokina, Doctor of Medical Sciences, Leading Researcher, Research Laboratory of Immunopathology and Immunodiagnostics of Tuberculosis Infection
127473, Moscow, 4 Dostoevsky Street, Building 2;
Tel.: +7 (495) 681-11-66
N. P. Doktorova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Natalya P. Doktorova, Candidate of Medical Sciences
Researcher, Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infection
127473, Moscow, 4 Dostoevsky Street, Building 2;
Tel.: +7 (495) 681-11-66
R. S. Ladieu
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Roman S. Ladieu, Junior Researcher, Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections
127473, Moscow, 4 Dostoevsky Street, Building 2;
Tel.: +7 (495) 681-11-66
A. G. Samoylova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Anastasiya G. Samoylova, Doctor of Medical Sciences
Deputy Director for Research
127473, Moscow, 4 Dostoevsky Street, Building 2;
Tel.: +7 (495) 681-11-66
References
1. Akulenok A., Leskova N. Pharmacoeconomic Analysis of a 6-month treatment regimen for patients with drug-resistant pulmonary tuberculosis in the Republic of Belarus // Recipe. – 2024. – Vol. 27, № 2. – P. 255–262. (In Russ)
2. Ivanov P.E. Clinical trials of pretomanid. Farmakologiya i Toksikologiya, 2019, vol. 83, no. 2, pp. 67–73. (In Russ.)
3. Komissarova O.G., Tikhonov A.M., Shorokhova V.A., Abdullaev R.Yu., Romanov V.V., Ergeshov A.E. Effectiveness and safety of the shorter B-Pa-L regimen in tuberculosis patients with multidrug and extensively drug-resistant pathogen. Tuberculosis and socially significant diseases, 2024, vol. 12, no. 4, pp. 72–73. (In Russ.) https://doi.org/10.54921/2413-0346-2024-12-4-67-80
4. Kuznetsova N.V. Influence of pretomanid on resistant strains of Mycobacterium tuberculosis. Voprosy Klinicheskoy Farmakologii, 2020, vol. 27, no. 8, pp. 84–90. (In Russ.)
5. Kukurika A.V. Pretomanid: Clinical trials and prospects to be used in treatment regimens for multiple and extensive drug resistant tuberculosis // Tuberculosis and Lung Diseases, 2021, vol. 99, no. 6, p. 54–60. (In Russ.) https://doi.org/10.21292/2075-1230-2021-99-6-54-60
6. Mozhokina G.N., Samoylova A.G., Vasilyeva I.A., Abramchenko A.V. Delamanid: Safety and efficacy analysis. Tuberculosis and Lung Diseases. 2023;101(6):102-110. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-6-102-110
7. Smailova G.A. A new anti-tuberculosis drug pretomanid for the treatment of drug-resistant TB (review). Actual Problems of Theoretical and Clinical Medicine, 2023, vol. 39, no. 1, pp. 65–72. (In Russ.) https://doi.org/ 10.24412/2790-1289-2023-1-65-72
8. Yatskevich N.V., Gurbanova E., Gurevich G.L., Skryagina E.M. Evaluation of Safety of 9- and 6-Month Treatment Regimens in Patients with Rifampicin-Resistant Tuberculosis in the Republic of Belarus. Tuberculosis and Lung Diseases. 2024;102(1):34-39. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-1-34-39
9. Berry C., du Cros P., Fielding K., Gajewski S., Kazounis E., McHugh T.D., Merle C., Motta I., Moore D.A.J., Nyang'wa B.T. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis // Trials. – 2022. – № 23. – Р. 484. https://doi.org/10.1186/s13063-022-06331-8
10. Bratkowska D., Shobo A., Singh S., Bester L.A., Kruger H.G., Maguire G.E., Govender T. Determination of the antitubercular drug PA-824 in rat plasma, lung and brain tissues by liquid chromatography tandem mass spectrometry: application to a pharmacokinetic study // J Chromatogr B Analyt Technol Biomed Life Sci. – 2015. – № 988. https://doi.org/10.1016/j.jchromb.2015.02.041
11. Cevik M., Thompson L.C., Upton C., Rolla V.C., Malahleha M., Mmbaga B., Ngubane N., Abu Bakar Z., Rassool M., Variava E., Dawson R., Staples S., Lalloo U., Louw C., Conradie F., Eristavi M., Samoilova A., Skornyakov S.N., Ntinginya N.E., Haraka F., Praygod G., Mayanja-Kizza H., Caoili J., Balanag V., Dalcolmo M.P., McHugh T., Hunt R., Solanki P., Bateson A., Crook A.M., Fabiane S., Timm J., Sun E., Spigelman M., Sloan D.J., Gillespie S.H. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial // Lancet Infect Dis. – 2024. – Vol. 24, № 9. – Р. 1003-1014. https://doi.org/10.1016/S1473-3099(24)00223-8
12. Conradie F., Bagdasaryan T.R., Borisov S., Howell P., Mikiashvili L., Ngubane N., Samoilova A., Skornykova S., Tudor E., Variava E., Yablonskiy P., Everitt D., Wills G.H., Sun E., Olugbosi M., Egizi E., Li M., Holsta A., Timm J., Bateson A., Crook A.M., Fabiane S.M., Hunt R., McHugh T.D., Tweed C.D., Foraida S., Mendel C.M., Spigelman M. Bedaquiline-Pretomanid-Linezol id Regimens for Drug-Resistant Tuberculosis // N Engl J Med. – 2022. – Vol. 387, № 9. – Р. 810-823. https://doi.org/10.1056/NEJMoa2119430
13. Conradie F., Diacon A.H., Ngubane N., Howell P., Everitt D., Crook A.M., Mendel C.M., Egizi E., Moreira J., Timm J., McHugh T.D., Wills G.H., Bateson A., Hunt R., van Niekerk C., Li M., Olugbosi M., Spigelman M. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis // N. Engl. J. Med. – 2020. – № 382. – P. 893-902. https://doi.org/10.1056/NEJMoa1901814
14. Daniel B.D., Shanmugam S., Mehta R., Bhalla M., Mariappan M., Ramraj B., Awasthi A.K., Patel P., Jain A., Jain P., Kumar C., Oswal V., Singla N., Kumar S., Dave J., Vadgama P., Bhatnagar A.K., Kant S., Prabhakaran R., Tamakuwala G., Mukherjee R.N., Santhanakrishnan R.K., Ravikumar D., Nagarajan N.K., Kumaravadivelu S., Bharathi J., Sridhar A., Ramachandran R., Matoo S.K., Ponnuraja C., Jaju J., Padmapriyadarsini C. Long-term outcomes in drug-resistant tuberculosis with bedaquiline, pretomanid and varying doses of linezolid // J. Infect. – 2025. – Vol. 91, № 1. – P. 106509. https://doi.org/10.1016/j.jinf.2025.106509
15. Dawson R., Diacon A.H., Everitt D., van Niekerk C., Donald P.R., Burger D.A., Schall R., Spigelman M., Conradie A., Eisenach K., Venter A., Ive P., Page-Shipp L., Variava E., Reither K., Ntinginya N.E., Pym A., Groote-Bidlingmaier F., Mendel C.M. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment // Lancet. – 2015. – № 385. – P. 1738-1747. https://doi.org/10.1016/S0140-6736(14)62002-X
16. De Miranda Silva C., Hajihosseini A., Myrick J., Nole J., Louie A., Schmidt S., Drusano G.L. Effect of moxifloxacin plus pretomanid against Mycobacterium tuberculosis in different metabolic states in vitro // Antimicrob. Agents Chemother. – 2018. – Vol. 63, № 1. – Р. e01695-18. https://doi.org/10.1128/AAC.01695-18
17. Diacon A.H., Dawson R., von Groote-Bidlingmaier F., Symons G., Venter A., Donald P.R., van Niekerk C., Everitt D., Winter H., Becker P., Mendel C.M. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline // Am. J. Respir. Crit. Care Med. – 2015. – Vol. 191, № 8. – P. 943-953. https://doi.org/10.1164/rccm.201410-1801OC
18. Diacon A.H., Dawson R., Hanekom M., Narunsky K., Maritz S.J., Venter A., Donald P.R., van Niekerk C., Whitney K., Rouse D.J., Laurenzi M.W., Ginsberg A.M., Spigelman M.K. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients // Antimicrob. Agents Chemother. – 2010. – Vol. 54, № 8. – P. 3402-3407. https://doi.org/10.1128/AAC.01354-09
19. Diacon A.H., Dawson R., von Groote-Bidlingmaier F., Symons G., Venter A., Donald P.R., van Niekerk C., Everitt D., Winter H., Becker P., Mendel C.M., Spigelman M.K. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations // Lancet. – 2012. – Vol. 380, № 9846. – P. 986-993. https://doi.org/10.1016/S0140-6736(12)61080-0
20. Dooley K.E., Hendricks B., Gupte N., Barnes G., Narunsky K., Whitelaw C., Smit T., Ignatius E.H., Friedman A., Dorman S.E., Dawson R. Assessing pretomanid for tuberculosis (APT): a randomized phase 2 trial // Am. J. Respir. Crit. Care Med. – 2023. – Vol. 207, № 7. – P. 929-935. https://doi.org/10.1164/rccm.202208-1475OC
21. Evans D., Hirasen K., Ramushu C., Long L., Sinanovic E., Conradie F., Howell P., Padanilam X., Ferreira H., Variava E., Rajaram S., Gupta A., Juneja S., Ndjeka N. Patient and provider costs of the BPaL regimen for drug-resistant tuberculosis // PLoS One. – 2024. – Vol. 19, № 10. – Р. e0309034. https://doi.org/10.1371/journal.pone.0309034
22. Ginsberg A.M., Laurenzi M.W., Rouse D.J., Whitney K.D., Spigelman M.K. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects // Antimicrob. Agents Chemother. – 2009. – № 53. – P. 3720-3725. https://doi.org/10.1128/AAC.00106-09
23. Gomez G.B., Siapka M., Conradie F., Ndjeka N., Garfin A.M.C., Lomtadze N., Avaliani Z., Kiria N., Malhotra S., Cook-Scalise S., Juneja S., Everitt D., Spigelman M., Vassall A. Cost-effectiveness of bedaquiline, pretomanid and linezolid // BMJ Open. – 2021. – Vol. 11, № 12. – Р. e051521. https://doi.org/10.1136/bmjopen-2021-051521
24. Hasan T., Medcalf E., Nyang’wa B.T., Egizi E., Berry C., Dodd M., Foraida S., Gegia M., Li M., Mirzayev F., Morgan H., Motta I., Nguyen L., Schumacher S., Schlub T., Fox G. Safety and tolerability of linezolid in BPaL regimens // Clin. Infect. Dis. – 2024. – Vol. 78, № 3. – P. 730–741. https://doi.org/10.1093/cid/ciad653
25. Howell P., Upton C., Mvuna N., Olugbosi M. Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid // BMJ Case Rep. – 2021. – Vol. 14, № 12. – Р. e245612. https://doi.org/10.1136/bcr-2021-245612
26. Ignatius E.H., Abdelwahab M.T., Hendricks B., Gupte N., Narunsky K., Wiesner L., Barnes G., Dawson R., Dooley K.E., Denti P. Pretomanid pharmacokinetics in the presence of rifamycins // Antimicrob. Agents Chemother. – 2021. – Vol. 65, № 2. – Р. e01196-е01220. https://doi.org/10.1128/AAC.01196-20
27. Keam S.J. Pretomanid: first approval // Drugs. – 2019. – Vol. 79, № 16. – P. 1797-1803. https://doi.org/10.1007/s40265-019-01207-9
28. LaHood A., Rahman R., McKenna L., Frick M., Mitnick C.D. Comparing timelines and evidence for TB, HIV and HCV drug approvals // PLoS One. – 2022. – Vol. 17, № 7. – Р. e0271102. – https://doi.org/10.1371/journal.pone.0271102
29. Lenaerts A.J., Gruppo V., Marietta K.S., Johnson C.M., Driscoll D.K., Tompkins N.M., Rose J.D., Reynolds R.C., Orme I.M. Preclinical testing of PA-824 // Antimicrob. Agents Chemother. – 2005. – Vol. 49, № 6. – P. 2294-2301. https://doi.org/10.1128/AAC.49.6.2294-2301.2005
30. Li M., Saviolakis G.A., El-Amin W., Makhene M.K., Osborn B., Nedelman J., Yang T.J., Everitt D. Phase 1 study of pretomanid effects on QTc interval // Clin. Pharmacol. Drug Dev. – 2021. – Vol. 10, № 6. – P. 634-646. https://doi.org/10.1002/cpdd.898
31. Liu Y., Tan Y., Wei G., Lu Z., Liu Y., Yang B., Hui A.M., Li K. Safety and pharmacokinetics of pretomanid in healthy Chinese adults // Pulm. Pharmacol. Ther. – 2022. – № 73-74. – P. 102132. https://doi.org/10.1016/j.pupt.2022.102132
32. Lyons M.A. Pretomanid dose selection using optimization approaches // CPT Pharmacometrics Syst. Pharmacol. – 2021. – Vol. 10, № 3. – P. 211-219. https://doi.org/10.1002/psp4.12591
33. Motta I., Cusinato M., Ludman A.J., Lachenal N., Dodd M., Soe M., Abdrasuliev T., Usmanova R., Butabekov I., Nikolaevna T.Z., Liverko I., Parpieva N., Moodliar R., Solodovnikova V., Kazounis E., Nyang’wa B.T., Fielding K.L., Berry C. QTc prolongation in rifampicin-resistant tuberculosis // Antimicrob. Agents Chemother. – 2024. – Vol. 68, № 7. – e00536-е00624. https://doi.org/10.1128/AAC.00536-24
34. Nguyen T.V.A., Nguyen Q.H., Nguyen T.N.T., Anthony R.M., Vu D.H., Alffenaar J.C. Pretomanid resistance: mechanisms and clinical relevance // Int. J. Antimicrob. Agents. – 2023. – Vol. 62, № 4. – P. 106953. https://doi.org/10.1016/j.ijantimicag.2023.106953
35. Nuermberger E.L., Yoshimatsu T., Tyagi S., et al. Combination chemotherapy with PA-824 and moxifloxacin // Antimicrob. Agents Chemother. – 2008. – Vol. 52, № 4. – P. 1522-1529. https://doi.org/10.1128/AAC.01211-07
36. Nyang’wa B.T., Berry C., Kazounis E., Motta I., Parpieva N., Tigay Z., Moodliar R., Dodd M., Solodovnikova V., Liverko I., Rajaram S., Rassool M., McHugh T., Spigelman M., Moore D.A., Ritmeijer K., du Cros P., Fielding K. Short oral regimens for rifampicin-resistant tuberculosis (TB-PRACTECAL) // Lancet Respir. Med. – 2024. – Vol. 12, № 2. – P. 117-128. https://doi.org/10.1016/S2213-2600(23)00389-2
37. Padmapriyadarsini C., Oswal V.S., Jain C.D., Mariappan M.V., Singla N., Kumar S., Daniel B.D., Dave J.D., Vadgama P., Ramraj B., Kant S., Bhatnagar A.K., Shanmugam S., Paul D., Bharathi J., Palav M., Shah N.V., Santhanakrishnan R., Dewan R.K., Shekh N., Rathinam P., Sisara A.B., Mankar S.D., Bajpai J., Mittal U., Chauhan S., Kumar R., Parmar M., Mattoo S.K., Jaju J. Effectiveness and safety of varying doses of linezolid with BPaL // Clin. Infect. Dis. – 2024. – Vol. 79, № 6. – P. 1375-1385. https://doi.org/10.1093/cid/ciae388
38. Showalter H.D. Progress in development of nitroimidazooxazines // Molecules. – 2020. – Vol. 25, № 18. – P. 4137. https://doi.org/10.3390/molecules25184137
39. Silva D.R., Fernandes F.F., Ferreira J.C., Bernando W., Dalcolmo M.M.P., Johansen F.D.C., Mello F.C.Q. BPaLM for drug-resistant tuberculosis: systematic review // J. Bras. Pneumol. – 2025. – Vol. 50, № 6. – Р. e20240295. https://doi.org/10.36416/1806-3756/e20240295
40. Singh R., Manjunatha U., Boshoff H.I., Ha Y.H., Niyomrattanakit P., Ledwidge R., Dowd C.S., Lee I.Y., Kim P., Zhang L., Kang S., Keller T.H., Jiricek J., Barry C.E. PA-824 mechanism via nitric oxide release // Science. – 2008. – Vol. 322, № 5906. – P. 1392-1395. https://doi.org/10.1126/science.1164571
41. Stover C.K., Warrener P., VanDevanter D.R., Sherman D.R., Arain T.M., Langhorne M.H., Anderson S.W., Towell J.A., Yuan Y., McMurray D.N., Kreiswirth B.N., Barry C.E., Baker W.R. Nitroimidazopyran drug candidate for tuberculosis // Nature. – 2000. – № 405. – P. 962-966. https://doi.org/10.1038/35016103
42. Tasneen R., Tyagi S., Williams K., Grosset J., Nuermberger E. Enhanced bactericidal activity of rifampin with PA-824 // Antimicrob. Agents Chemother. – 2008. – Vol. 52, № 10. – P. 3664-3668. https://doi.org/10.1128/AAC.00686-08
43. TB Alliance. PA-824: Phase 1 clinical study summary. – 2005. – Available at: https://www.tballiance.org [Accessed 27.09.2024].
44. Timm J., Bateson A., Solanki P., Paleckyte A., Witney A.A., Rofael S.A.D., Fabiane S., Olugbosi M., McHugh T.D., Sun E. Resistance to bedaquiline, linezolid and pretomanid // PLOS Glob. Public Health. – 2023. – Vol. 3, № 10. – Р. e0002283. https://doi.org/10.1371/journal.pgph.0002283
45. Tweed C.D., Wills G.H., Crook A.M., Amukoye E., Balanag V., Ban A.Y.L., Bateson A.L.C., Betteridge M.C., Brumskine W., Caoili J., Chaisson R.E., Cevik M., Conradie F., Dawson R., Del Parigi A., Diacon A., Everitt D.E., Fabiane S.M., Hunt R., Ismail A.I., Lalloo U., Lombard L., Louw C., Malahleha M., McHugh T.D., Mendel C.M., Mhimbira F., Moodliar R.N., Nduba V., Nunn A.J., Sabi I., Sebe M.A., Selepe R.A.P., Staples S., Swindells S., van Niekerk C.H., Variava E., Spigelman M., Gillespie S.H. Trial of pretomanid, moxifloxacin and pyrazinamide // Int. J. Tuberc. Lung Dis. – 2021. – Vol. 25, № 4. – P. 305-314. https://doi.org/10.5588/ijtld.20.0513
46. Tyagi S., Nuermberger E., Yoshimatsu T., Williams K., Rosenthal I., Lounis N., Bishai W., Grosset J. Bactericidal activity of PA-824 in murine tuberculosis // Antimicrob. Agents Chemother. – 2005. – Vol. 49, № 6. – P. 2289-2293. https://doi.org/10.1128/AAC.49.6.2289-2293.2005
47. Winter H., Egizi E., Erondu N., Ginsberg A., Rouse D.J., Severynse-Stevens D., Pauli E., Everitt D. Pharmacokinetic interaction between PA-824 and midazolam // Antimicrob. Agents Chemother. – 2013. – Vol. 57, № 8. – P. 3699-3703. https://doi.org/10.1128/AAC.02632-12
48. Xu J., Li S.Y., Almeida D.V., Tasneen R., Barnes K., Converse P.J., Upton A.M., Mdluli K., Fotouhi N., Nuermberger E.L. Contribution of pretomanid to novel regimens in murine tuberculosis // Antimicrob. Agents Chemother. – 2019. – Vol. 63, № 5. – Р. e00019. https://doi.org/10.1128/AAC.00019-19
Review
For citations:
Gayda A.I., Mozhokina G.N., Doktorova N.P., Ladieu R.S., Samoylova A.G. Pretomanid: From Development to the Implementation of Short-Term Tuberculosis Chemotherapy Regimens: A Literature Review. Tuberculosis and Lung Diseases. 2026;104(3):88-97. (In Russ.) https://doi.org/10.58838/2075-1230-2026-104-3-88-97
Views:
58
JATS XML
Email this article 